Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to [email protected].

November 18, 2025

Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women’s Health

Download PDF

June 4, 2025

Mycovia Pharmaceuticals, Inc. Announces First Participant Enrolled in an Investigator-Initiated Phase 2 Study for Cryptococcal Meningitis

Download PDF

April 2, 2025

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s Recognition for the Inclusion of VIVJOA® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug List

Download PDF

August 1, 2024

Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting

Download PDF

March 26, 2024

Mycovia Pharmaceuticals, Inc. Announces AllianceRx Walgreens Pharmacy and Walgreens Community-based Specialty Pharmacies as Exclusive Distributor of VIVJOA®

Download PDF
Transforming healthcare together Careers at Mycovia
Working together to transform healthcare Contact Us